Imbria's Promising Results in Cardiac Trials Boosts Efficacy Profile

Imbria Pharmaceuticals' fatty acid oxidation inhibitor showed promising results in a Phase II trial for non-obstructive hypertrophic cardiomyopathy (nHCM), suggesting potential efficacy in a separate heart failure trial. nHCM affects around one in 500 people, while heart failure with preserved ejection fraction (HFpEF) affects an estimated 2% of the population. Imbria's ninerafaxstat is currently in Phase II development for both conditions.